Affordable Access

deepdyve-link
Publisher Website

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

Authors
  • Millward, Michael
  • Mainwaring, Paul
  • Mita, Alain
  • Federico, Kristine
  • Lloyd, G K
  • Reddinger, Natasha
  • Nawrocki, Steffan
  • Mita, Monica
  • Spear, Matthew A
Type
Published Article
Journal
Investigational New Drugs
Publisher
Springer-Verlag
Publication Date
Jun 01, 2012
Volume
30
Issue
3
Pages
1065–1073
Identifiers
DOI: 10.1007/s10637-011-9642-4
PMID: 21327495
Source
Medline
License
Unknown

Abstract

The combination of full doses of plinabulin and docetaxel is tolerable. With encouraging antitumor activity, this supported further development of this combination.

Report this publication

Statistics

Seen <100 times